Hormonal
Maintaining serum Lipoprotein(a) [Lp(a)] levels below 298 mg/L is associated with a delay in the progression of coronary artery disease severity.
If you have heart disease, ask your doctor to check your Lipoprotein(a) level. The study suggests keeping it below 298 mg/L. Unlike other cholesterol markers, Lp(a) is largely genetic and doesn't drop significantly with diet or exercise alone, so you may need specific medical therapies to manage it.
our findings indicate that maintaining serum Lp(a) levels below 298 mg/L may potentially delay the progression of CHD.
Why this rating
Cross-sectional study; identifies cutoff but does not test an intervention.
Source
Establishment of precise prevention strategies for the occurrence and progression of coronary atherosclerotic heart disease using machine learning
Qingfeng Wu et al. · Heliyon · 2024
DOI 10.1016/j.heliyon.2024.e35797
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →